| __timestamp | Axsome Therapeutics, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 302156000 |
| Thursday, January 1, 2015 | 2419289 | 402271000 |
| Friday, January 1, 2016 | 6343648 | 476593000 |
| Sunday, January 1, 2017 | 7206691 | 554336000 |
| Monday, January 1, 2018 | 9351522 | 604353000 |
| Tuesday, January 1, 2019 | 13598030 | 680924000 |
| Wednesday, January 1, 2020 | 28896749 | 737669000 |
| Friday, January 1, 2021 | 66646205 | 759375000 |
| Saturday, January 1, 2022 | 159253661 | 854009000 |
| Sunday, January 1, 2023 | 323123000 | 937300000 |
| Monday, January 1, 2024 | 411359000 | 1009025000 |
Unleashing insights
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of BioMarin Pharmaceutical Inc. and Axsome Therapeutics, Inc. over the past decade. BioMarin, a seasoned player, consistently spent more on SG&A, peaking at approximately $937 million in 2023. In contrast, Axsome, a rising star, saw its SG&A expenses skyrocket by over 23,000% from 2014 to 2023, reaching around $323 million. This dramatic increase reflects Axsome's aggressive growth strategy. While BioMarin's expenses grew steadily, Axsome's rapid escalation highlights its transition from a small-cap to a more established biotech firm. Understanding these trends offers insights into each company's strategic priorities and market positioning. As the biotech landscape evolves, monitoring SG&A efficiency remains vital for investors and stakeholders.
Amgen Inc. and Axsome Therapeutics, Inc.: SG&A Spending Patterns Compared
Regeneron Pharmaceuticals, Inc. vs Axsome Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Summit Therapeutics Inc. or Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. and ACADIA Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Novavax, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and Veracyte, Inc.
Axsome Therapeutics, Inc. vs Geron Corporation: SG&A Expense Trends
Axsome Therapeutics, Inc. vs Galapagos NV: SG&A Expense Trends